<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Liver Health on FinanClub</title>
    <link>https://finan.club/tags/liver-health/</link>
    <description>Recent content in Liver Health on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 25 Mar 2024 09:02:19 +0000</lastBuildDate><atom:link href="https://finan.club/tags/liver-health/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>CBAY</title>
      <link>https://finan.club/us/cbay/</link>
      <pubDate>Mon, 25 Mar 2024 09:02:19 +0000</pubDate>
      
      <guid>https://finan.club/us/cbay/</guid>
      <description>score:96
Chances: Gilead Sciences, Inc. has completed the acquisition of CymaBay Therapeutics, Inc. for $4.3 billion in total equity value, adding to its liver portfolio and aligning with its commitment to liver health. CymaBayâ€™s lead product candidate, seladelpar, for the treatment of primary biliary cholangitis (PBC) including pruritus, has shown promising results in clinical trials.</description>
    </item>
    
  </channel>
</rss>
